If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Blood plasma is a light amber-colored liquid component of blood in which blood cells are absent, but which contains proteins and other constituents of whole blood in suspension. It makes up about 55% of the body's total blood volume. It is the intravascular part of extracellular fluid (all body fluid outside cells). It is mostly water (up to 95% by volume), and contains important dissolved proteins (6–8%; e.g., serum albumins, globulins, and fibrinogen), glucose, clotting factors, electrolytes (Na+, Ca2+, Mg2+, HCO3−, Cl−, etc.), hormones, carbon dioxide (plasma being the main medium for excretory product transportation), and oxygen. It plays a vital role in an intravascular osmotic effect that keeps electrolyte concentration balanced and protects the body from infection and other blood-related disorders. Blood plasma can be separated from whole blood through blood fractionation, by adding an anticoagulant to a tube filled with blood, which is spun in a centrifuge until the blood cells fall to the bottom of the tube. The blood plasma is then poured or drawn off. For point-of-care testing applications, plasma can be extracted from whole blood via filtration or via agglutination to allow for rapid testing of specific biomarkers. Blood plasma has a density of approximately 1,025 kg/m3 (1.025 g/ml). Blood serum is blood plasma without clotting factors. Plasmapheresis is a medical therapy that involves blood plasma extraction, treatment, and reintegration.
== External links == GMD MS Spectrum American Chemical Society (21 April 2010). "Ancestral Eve' Crystal May Explain Origin of Life's Left-Handedness". ScienceDaily. Archived from the original on 23 April 2010. Retrieved 2010-04-21.
South Africa In South Africa, the five-door-only 323 proved an immediate success. The 1.3 was gradually replaced by the larger 1.4 from July 1978, while a Special and a CS model were added at the low and high ends of the lineup respectively, complementing the existing De Luxe models. Well-equipped versions of the 1978 facelift model were sold as the "323 GLC" in South Africa. A 1600-cc model was also available in South Africa – however this model did not have a Mazda engine, unlike the rest of the range. To satisfy that country's local content regulations, a locally built Mitsubishi Saturn 1.6-litre unit was used. This produces 77 PS (57 kW) and was the most powerful engine to be installed in the FA-series Familia/323. It arrived in early 1979, but period testers felt that the less-revvy 1.6 provided very little that the 1.4 did not offer, and could not be considered to be worth the price. Fuel consumption dropped, while top speed of 148 km/h (92 mph) was only marginally higher than the 145 km/h (90 mph) of the smaller version. Sigma also fielded a rotary-engined 323 in the South African national rally championship.
Sources: en.wikipedia.org
The Standards for Reporting Enzymology Data guidelines provide minimum information required to comprehensively report kinetic and equilibrium data from investigations of enzyme activities including corresponding experimental conditions. The guidelines have been developed to report functional enzyme data with rigor and robustness.
IUPAC recommends the names lanthanoids and actinoids to avoid ambiguity, as the -ide suffix typically denotes a negative ion; however lanthanides and actinides remain common. With the increasing recognition of lutetium and lawrencium as d-block elements, some authors began to define the lanthanides as La–Yb and the actinides as Ac–No, matching the f-block. The transactinides or superheavy elements are the short-lived elements beyond the actinides, starting at lawrencium or rutherfordium (depending on where the actinides are taken to end). Many more categorizations exist and are used according to certain disciplines. In astrophysics, a metal is defined as any element with atomic number greater than 2, i.e. anything except hydrogen and helium. The term "semimetal" has a different definition in physics than it does in chemistry: bismuth is a semimetal by physical definitions, but chemists generally consider it a metal. A few terms are widely used, but without any very formal definition, such as "heavy metal", which has been given such a wide range of definitions that it has been criticized as "effectively meaningless". The scope of terms varies significantly between authors. For example, according to IUPAC, the noble gases extend to include the whole group, including the very radioactive superheavy element oganesson. However, among those who specialize in the superheavy elements, this is not often done: in this case "noble gas" is typically taken to imply the unreactive behaviour of the lighter elements of the group.
Education in spiritual and religious matters is also required by the American Psychiatric Association, however, far less attention is paid to the damage that more rigid, fundamentalist faiths commonly practiced in the United States can cause. This theme has been widely politicized in 2018 such as with the creation of the Religious Liberty Task Force in July of that year. Also, many providers and practitioners in the United States are only beginning to realize that the institution of mental healthcare lacks knowledge and competence of many non-Western cultures, leaving providers in the United States ill-equipped to treat patients from different cultures.
Sources: en.wikipedia.org
== Mechanical properties == As noted above, the (two-dimensional) density of graphene is 0.762 mg per square meter. Graphene is the strongest material ever tested, with an intrinsic tensile strength of 130 GPa (19,000,000 psi) (with representative engineering tensile strength ~50-60 GPa for stretching large-area freestanding graphene) and a Young's modulus (stiffness) close to 1 TPa (150,000,000 psi). The Nobel announcement illustrated this by saying that a 1 square meter graphene hammock would support a 4 kg cat but would weigh only as much as one of the cat's whiskers, at 0.77 mg (about 0.001% of the weight of 1 m2 of paper). Large-angle bending of graphene monolayers with minimal strain demonstrates its mechanical robustness. Even under extreme deformation, monolayer graphene maintains excellent carrier mobility. The spring constant of suspended graphene sheets has been measured using an atomic force microscope (AFM). Graphene sheets were suspended over SiO2 cavities where an AFM tip was used to apply stress to the sheet to test its mechanical properties. Its spring constant was in the range 1–5 N/m and the stiffness was 0.5 TPa, which differs from that of bulk graphite. These intrinsic properties could lead to applications such as NEMS as pressure sensors and resonators. Due to its large surface energy and out of plane ductility, flat graphene sheets are unstable with respect to scrolling, i.e. bending into a cylindrical shape, which is its lower-energy state.
=== Coronary heart disease risk === Arterial damage results from white blood cell invasion and inflammation within the wall. CRP is a general marker for inflammation and infection, so it can be used as a very rough proxy for heart disease risk. Since many things can cause elevated CRP, this is not a very specific prognostic indicator. Nevertheless, a level above 2.4 mg/L has been associated with a doubled risk of a coronary event compared to levels below 1 mg/L; however, the study group in this case consisted of patients who had been diagnosed with unstable angina pectoris; whether elevated CRP has any predictive value of acute coronary events in the general population of all age ranges remains unclear. Currently, C-reactive protein is not recommended as a cardiovascular disease screening test for average-risk adults without symptoms. The American Heart Association and U.S. Centers for Disease Control and Prevention have defined risk groups as follows:
Ulrich Hersel; Claudia Dahmen; Horst Kessler (2003). "RGD modified polymers: biomaterials for stimulated cell adhesion and beyond". Biomaterials. 24 (24): 4385–4415. doi:10.1016/s0142-9612(03)00343-0. PMID 12922151. Wikidata Q34223126. Marco Arnold; Elisabetta A Cavalcanti-Adam; Roman Glass; Jacques Blümmel; Wolfgang Eck; Martin Kantlehner; Horst Kessler; Joachim P Spatz (2004). "Activation of integrin function by nanopatterned adhesive interfaces". ChemPhysChem. 5 (3): 383–388. doi:10.1002/cphc.200301014. PMID 15067875. Wikidata Q44832858. Kessler, Horst (July 1982). "Conformation and Biological Activity of Cyclic Peptides". Angewandte Chemie International Edition in English. 21 (7): 512–523. doi:10.1002/anie.198205121. ISSN 0570-0833. Dechantsreiter MA; Planker E; Mathä B; Lohof E; Hölzemann G; Jonczyk A; Goodman SL; Kessler H (1999). "N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists". Journal of Medicinal Chemistry. 42 (16): 3033–3040. doi:10.1021/jm970832g. PMID 10447947. Wikidata Q30580638. Elisabetta A Cavalcanti-Adam; Tova Volberg; Alexandre Micoulet; Horst Kessler; Benjamin Geiger; Joachim Pius Spatz (2007). "Cell spreading and focal adhesion dynamics are regulated by spacing of integrin ligands". Biophysical Journal. 92 (8): 2964–2974. doi:10.1529/biophysj.106.089730. PMC 1831685. PMID 17277192. Wikidata Q30479140. Kessler, Horst (2023). NMR: Mein Kompass in der Organischen und Medizinischen Chemie [NMR: my compass in organic and medicinal chemistry]. Berlin: GNT Publishing GmbH. ISBN 978-3-86225-132-2.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.